L. Uharek

2.5k total citations
57 papers, 1.6k citations indexed

About

L. Uharek is a scholar working on Hematology, Immunology and Oncology. According to data from OpenAlex, L. Uharek has authored 57 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Hematology, 29 papers in Immunology and 14 papers in Oncology. Recurrent topics in L. Uharek's work include Hematopoietic Stem Cell Transplantation (28 papers), Immune Cell Function and Interaction (17 papers) and Immunotherapy and Immune Responses (12 papers). L. Uharek is often cited by papers focused on Hematopoietic Stem Cell Transplantation (28 papers), Immune Cell Function and Interaction (17 papers) and Immunotherapy and Immune Responses (12 papers). L. Uharek collaborates with scholars based in Germany, United States and United Kingdom. L. Uharek's co-authors include E. Thiel, B. Glaß, Norbert Schmitz, Chiara Gentilini, Jörg Steinmann, Matthias Zeis, Peter Dreger, Ulrike Koehl, Kathrin Rieger and W Mueller-Ruchholtz and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Gut.

In The Last Decade

L. Uharek

56 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
L. Uharek Germany 22 796 795 438 302 223 57 1.6k
A Iacone Italy 20 585 0.7× 381 0.5× 451 1.0× 193 0.6× 312 1.4× 82 1.5k
Robert Chiesa United Kingdom 25 657 0.8× 529 0.7× 621 1.4× 307 1.0× 297 1.3× 61 1.7k
Karin Bilger France 21 873 1.1× 343 0.4× 339 0.8× 520 1.7× 134 0.6× 41 1.6k
Mikio Ueda Japan 18 462 0.6× 422 0.5× 214 0.5× 195 0.6× 125 0.6× 71 1.1k
Kazuhiro Masuoka Japan 21 588 0.7× 378 0.5× 326 0.7× 198 0.7× 124 0.6× 50 1.1k
Liang Piu Koh Singapore 17 597 0.8× 216 0.3× 328 0.7× 400 1.3× 183 0.8× 80 1.3k
Susan L. Heatley Australia 18 507 0.6× 752 0.9× 165 0.4× 312 1.0× 371 1.7× 51 1.7k
Motohiro Hamaguchi Japan 21 951 1.2× 191 0.2× 214 0.5× 272 0.9× 330 1.5× 69 1.7k
R. M. Minchinton Australia 20 653 0.8× 812 1.0× 122 0.3× 205 0.7× 124 0.6× 61 1.6k
Erlie Jiang China 20 633 0.8× 280 0.4× 307 0.7× 305 1.0× 343 1.5× 202 1.5k

Countries citing papers authored by L. Uharek

Since Specialization
Citations

This map shows the geographic impact of L. Uharek's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by L. Uharek with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites L. Uharek more than expected).

Fields of papers citing papers by L. Uharek

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by L. Uharek. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by L. Uharek. The network helps show where L. Uharek may publish in the future.

Co-authorship network of co-authors of L. Uharek

This figure shows the co-authorship network connecting the top 25 collaborators of L. Uharek. A scholar is included among the top collaborators of L. Uharek based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with L. Uharek. L. Uharek is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Schroeder, Thomas, Akos Czibere, Uwe Platzbecker, et al.. (2013). Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation. Leukemia. 27(6). 1229–1235. 166 indexed citations
2.
3.
Schulze, Harald, et al.. (2011). A new HLA‐B*52 allele, B*52:23, detected in a patient before bone marrow transplantation. Tissue Antigens. 78(6). 455–456. 3 indexed citations
4.
Brestrich, Gordon, Annika Fischer, Markus Hammer, et al.. (2009). Adoptive T-Cell Therapy of a Lung Transplanted Patient with Severe CMV Disease and Resistance to Antiviral Therapy. American Journal of Transplantation. 9(7). 1679–1684. 81 indexed citations
5.
Heringer‐Walther, Silvia, Klaus Eckert, L. Uharek, et al.. (2009). Angiotensin-(1-7) stimulates hematopoietic progenitor cells in vitro and in vivo. Haematologica. 94(6). 857–860. 59 indexed citations
6.
Tramsen, Lars, Ulrike Koehl, Torsten Tonn, et al.. (2008). Clinical-scale generation of human anti-Aspergillus T cells for adoptive immunotherapy. Bone Marrow Transplantation. 43(1). 13–19. 50 indexed citations
7.
Schmidt‐Hieber, Martin, Igor Wolfgang Blau, Stefan Schwartz, et al.. (2007). Intensified Strategies to Control Vancomycin-Resistant Enterococci in Immunocompromised Patients. International Journal of Hematology. 86(2). 158–162. 27 indexed citations
8.
Ganepola, Susanne, Chiara Gentilini, Thoralf Lange, et al.. (2007). Patients at high risk for CMV infection and disease show delayed CD8+ T-cell immune recovery after allogeneic stem cell transplantation. Bone Marrow Transplantation. 39(5). 293–299. 71 indexed citations
9.
Penack, Olaf, Lars Fischer, Andrea Stroux, et al.. (2007). Serotherapy with thymoglobulin and alemtuzumab differentially influences frequency and function of natural killer cells after allogeneic stem cell transplantation. Bone Marrow Transplantation. 41(4). 377–383. 18 indexed citations
10.
Wolff, Daniel, Stefan Wilhelm, J. Hahn, et al.. (2006). Replacement of calcineurin inhibitors with daclizumab in patients with transplantation-associated microangiopathy or renal insufficiency associated with graft-versus-host disease. Bone Marrow Transplantation. 38(6). 445–451. 42 indexed citations
11.
Fietz, Thomas, L. Uharek, Chiara Gentilini, et al.. (2005). Allogeneic hematopoietic cell transplantation following conditioning with90Y-ibritumomab-tiuxetan. Leukemia & lymphoma. 47(1). 59–63. 23 indexed citations
12.
Lange, Thoralf, Michael W. Deininger, R. Brand, et al.. (2004). BCR-ABL transcripts are early predictors for hematological relapse in chronic myeloid leukemia after hematopoietic cell transplantation with reduced intensity conditioning. Leukemia. 18(9). 1468–1475. 19 indexed citations
13.
Zeis, Matthias, et al.. (2002). Idiotype protein-pulsed dendritic cells produce strong anti-myeloma effects after syngeneic stem cell transplantation in mice. Bone Marrow Transplantation. 29(3). 213–221. 10 indexed citations
14.
15.
16.
Dreger, Peter, Nils von Neuhoff, R. Kuse, et al.. (1998). Early stem cell transplantation for chronic lymphocytic leukaemia: a chance for cure?. British Journal of Cancer. 77(12). 2291–2297. 43 indexed citations
17.
Dreger, Peter, Nils von Neuhoff, R. Kuse, et al.. (1997). Sequential high-dose therapy and autologous stem cell transplantation for treatment of mantle cell lymphoma. Annals of Oncology. 8(4). 401–403. 19 indexed citations
18.
Zeis, Matthias, L. Uharek, B. Glaß, et al.. (1997). Allogeneic MHC‐mismatched activated natural killer cells administered after bone marrow transplantation provide a strong graft‐versus‐leukaemia effect in mice. British Journal of Haematology. 96(4). 757–761. 44 indexed citations
19.
Zeis, Matthias, L. Uharek, B. Glaß, et al.. (1994). Induction of graft-versus-leukemia (GVL) activity in murine leukemia models after IL-2 pretreatment of syngeneic and allogeneic bone marrow grafts.. PubMed. 14(5). 711–5. 15 indexed citations
20.
Haferlach, Torsten, W. Gaßmann, L. Uharek, Markus Tiemann, & H. Löffler. (1993). Mitoxantrone, Etoposide and Prednisolone (NOVEP) in Previously Untreated Elderly Patients with Non-Hodgkin’s Lymphoma (NHL) and as Salvage Therapy for Refractory NHL. Oncology Research and Treatment. 16(6). 440–445. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by A Iacone Breakdown of academic impact, for papers by Robert Chiesa Breakdown of academic impact, for papers by Karin Bilger Breakdown of academic impact, for papers by Mikio Ueda Breakdown of academic impact, for papers by Kazuhiro Masuoka Breakdown of academic impact, for papers by Liang Piu Koh Breakdown of academic impact, for papers by Susan L. Heatley Breakdown of academic impact, for papers by Motohiro Hamaguchi Breakdown of academic impact, for papers by R. M. Minchinton Breakdown of academic impact, for papers by Erlie Jiang
Rankless by CCL
2026